METUPUK(@METUPUKorg) 's Twitter Profile Photo

Philippa was diagnosed ER+ HER2- BC & no family history of BC, told she was 'low risk' of recurrence. It came back 6 mths after finishing treatment & changed subtype to mTNBC
TNBC is ~10-15% of all BC & MBC can switch subtype
She started the Trodelvy campaign!

account_circle
Marta Perachino(@MartaPerachino) 's Twitter Profile Photo

344 pts w/ HR+mBC, 95 mTNBC, 42 HER2+ mBC tested cfDNA baseline and before subsequent lines
🔍progressively ↘️ of actionable mutations across all MBC subtypes, while new target alterations continued to emerge, particularly in HR+
OncoAlert⁩ nature.com/articles/s4152…

account_circle
Armando Orlandi(@ArmandOrlandi) 's Twitter Profile Photo

🚨🏄‍♂️Olaparib in maintenance in all comers for gBRCA mTNBC: no thanks!NO positive KEYLINK-009! Good Tox profile for adjuvant post-NAC no pCR consideration! OncoAlert

🚨🏄‍♂️Olaparib in maintenance in all comers for gBRCA mTNBC: no thanks!NO positive KEYLINK-009! Good Tox profile for adjuvant post-NAC no pCR consideration! @OncoAlert #SABCS23
account_circle
Flavia Jacobs(@FlaviaJacobs_) 's Twitter Profile Photo

I am proud to have contributed to this post-hoc analysis of study evaluating relationship of diarrhea and neutropenia with outcomes in mTNBC treated with

Thank you to my mentor for this year Evandro de Azambuja, MD, PhD Elisa Agostinetto ESMO - Eur. Oncology OncoAlert

I am proud to have contributed to this post-hoc analysis of #ASCENT study evaluating relationship of diarrhea and neutropenia with outcomes in mTNBC treated with #Sacituzumab

Thank you to my mentor for this year @E_de_Azambuja @ElisaAgostinett @myESMO @OncoAlert #ESMOBreast23
account_circle
Kevin Punie(@kevinpunie) 's Twitter Profile Photo


🔹PFS and OS are similar between olaparib-pembrolizumab and CT-pembrolizumab maintenance in ITT population first line
🔹positive trends for PFS and OS for patients with tBRCA mutations
Hope Rugo
@Oncoalert SABCS

#SABCS23 #KeyLynk009
🔹PFS and OS are similar between olaparib-pembrolizumab and CT-pembrolizumab maintenance in ITT population first line #mTNBC
🔹positive trends for PFS and OS for patients with tBRCA mutations
@hoperugo
@Oncoalert @SABCSSanAntonio #bcsm
account_circle
Nina🧜🏽‍♀️(@NinaWil83565015) 's Twitter Profile Photo

I am so cold 🥶 I have my heat on 74, thick fuzzy socks on, I have blocked off doors not being used and am under the blankets with goosebumps, WTH? Is this chemo; blood thinners? I hate cancer!!!

account_circle
Nicola Fusco(@NicolaFuscoMD) 's Twitter Profile Photo

📢Our latest publication on test in is out now in CritRevOncolHematol 📚 We delve into the intricacies of CPS and share insights from along with nationwide survey. 🧪
🔗 authors.elsevier.com/a/1hbh23igGQks…

📢Our latest publication on #PDL1 #CPS test in #mTNBC is out now in CritRevOncolHematol 📚 We delve into the intricacies of CPS #testing  and share insights from #pathologists along with nationwide survey. 🧪 #bcsm #OncologyResearch #pathology 
🔗 authors.elsevier.com/a/1hbh23igGQks…
account_circle
Dr. Iván R. González(@Dr_Ivanoncologo) 's Twitter Profile Photo

📢 Valuable info from ANASTASE study: atezolizumab+nab-paclitaxel as 1st line tx safe & effective in PD-L1+. Results align w/ in terms of PFS & ORR.
ORR: 42.3% (95% CI: 28.9–55.7%).
PFS: 6.3 mos (95% CI: 3.9–8.7).
OS: 12mos 66.3% & 24mos 49.1%.
OncoAlert

📢 Valuable info from ANASTASE study: atezolizumab+nab-paclitaxel as 1st line tx safe & effective in #mTNBC PD-L1+. Results align w/ #IMpassion130 in terms of PFS & ORR.
ORR: 42.3% (95% CI: 28.9–55.7%).
PFS: 6.3 mos (95% CI: 3.9–8.7).
OS: 12mos  66.3% & 24mos 49.1%.
@OncoAlert…
account_circle
Arya Roy(@royaryam) 's Twitter Profile Photo

KEYLYNK-009 Hope Rugo shows no improvement in PFS with pembrolizumab + olaparib in unselected population with mTNBC. Positive PFS trend observed in tBRCAm pts. Observed better AE profile can lead to improved QoL
SABCS OncoAlert

KEYLYNK-009 @hoperugo shows no improvement in PFS with pembrolizumab + olaparib in unselected population with mTNBC. Positive PFS trend observed in tBRCAm pts. Observed better AE profile can lead to improved QoL
@SABCSSanAntonio #SABCS23 @OncoAlert
account_circle
Elisa Agostinetto(@ElisaAgostinett) 's Twitter Profile Photo

Congrats to Cedric Van Marke and Christine Desmedt awarded at with a Gilead Oncology grant for their projects:
- microbiome in patients treated with CDK4/6i! 🦠
- ADC and ICI targets in mTNBC from the KU Leuven autopsy program

OncoAlert Belgian Society of Medical Oncology

account_circle
Luca Visani(@LucaVisani2) 's Twitter Profile Photo

Stopping chemotherapy after disease response and continuing with pembro- olaparib showed similar outcomes for mTNBC patients in the KEYLYNK-009 trial as amazingly showed by Hope Rugo. Positive trend for PFS and OS in patients with tBRCA mutated patients.

Stopping chemotherapy after disease response and continuing with pembro- olaparib showed similar outcomes for mTNBC patients in the KEYLYNK-009 trial as amazingly showed by @hoperugo. Positive trend for PFS and OS in patients with tBRCA mutated patients.
#SABCS23 #BreastCancer
account_circle